A5052780521- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- Lymphoma Diagnosis and Treatment
- Genetics, Bioinformatics, and Biomedical Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- RNA Research and Splicing
- Multiple Myeloma Research and Treatments
- Advanced biosensing and bioanalysis techniques
- Chronic Myeloid Leukemia Treatments
- Chemical Synthesis and Analysis
- Click Chemistry and Applications
- Mosquito-borne diseases and control
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
University of Oxford
2020-2021
John Radcliffe Hospital
2020-2021
Centre de Recherche en Cancérologie de Marseille
2016
Inserm
2016
Aix-Marseille Université
2016
Centre National de la Recherche Scientifique
2016
Architecture et Fonction des Macromolécules Biologiques
2015
A midthroughput screening follow-up program targeting the first bromodomain of human BRD4 protein, BRD4(BD1), identified an acetylated-mimic xanthine derivative inhibitor. This compound binds with affinity in low micromolar range yet exerts suitable unexpected selectivity vitro against other members and extra-terminal domain (BET) family. structure-based pinpointed a role ZA loop, paving way for development potent selective BET-BRDi probes.
Protein–protein interactions (PPIs) represent an enormous source of opportunity for therapeutic intervention. We and others have recently pinpointed key rules that will help in identifying the next generation innovative drugs to tackle this challenging class targets within decade. used these design oriented chemical library corresponding a set diverse "PPI-like" modulators with cores identified as privileged structures therapeutics. In work, we purchased resulting 1664 structurally compounds...
A cell-based screening uses intracellular antibodies to select compounds targeting the chromosomal translocation protein LMO2.
Refractory T cell acute leukaemias that no longer respond to treatment would benefit from new modalities target cell-specific surface proteins. associated proteins (the surfaceome) offer possible therapy targets reduce tumour burden but also the leukaemia-initiating cells which tumours recur. Recent studies of leukaemia surfaceome confirmed CD7 is highly expressed in overt disease. We have used an anti-CD7 antibody drug conjugate (ADC) show binding protein results rapid internalization...
Macromolecules such as antibodies and antibody fragments have been reported to interfere with intracellular targets, but their use is limited delivery systems where expression achieved from vectors plasmids or viruses. We developed PEGylated nanoparticles of poly-lactic acid (PLA), including the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), which are functionalized monoclonal anti-CD7, anti-CD53, anti-GPR56 for receptor-mediated endocytic into T-cell leukemia cell lines....
The use of intracellular antibodies as templates to derive surrogate compounds is an important objective because can be employed initially for target validation in pre-clinical assays and subsequently compound library screens. LMO2 a T cell oncogenic protein activated the majority acute leukaemias. We have used inhibitory antibody fragment competitor small molecule screen using competitive surface plasmon resonance (cSPR) identify that bind LMO2. selected four but not when anti-LMO2 bound...